iThriveMD Review: The First GLP-1 Price Is Only Part of the Cost

At iThriveMD, the most important number is not necessarily the lowest price on the page. Compounded injectable semaglutide is advertised at $199 initially, while compounded injectable tirzepatide starts with a $299 promotional charge. Those figures sit alongside subsequent prices, prepaid packages, payment-plan offers and automatic renewal. For an adult comparing out-of-pocket care, the useful question is what will actually be collected now, what will recur later and what services that payment buys.

This documentary review examines iThriveMD’s published offerings and terms using sources consulted October 19, 2026. The clinic describes a broader longevity practice, with weight-management treatment available in person and through telehealth in California and Arizona. It provides considerable pricing detail, but not a fully reconciled payment schedule. The distinction between an introductory offer and an ongoing bill—explained further in our guide to the first GLP-1 payment—is particularly important here.

At a glance

Semaglutide introductory price: Compounded injectable semaglutide is advertised at $199 for the first month, then $299 per month; the monthly option says billing occurs every 28 days.
Sources: [5] [8]
Tirzepatide introductory price: Compounded injectable tirzepatide is advertised at $299 for the first month, then $399 per month, with billing every 28 days and no long-term commitment on that option.
Sources: [6] [8]
Prepayment and renewal: The homepage says packages are paid in full at purchase and automatically renew at the selected package interval; product pages also advertise payment plans without explaining their terms.
Sources: [8] [5] [6]
Microdosing package: The tirzepatide microdosing program lists $585 for 12 prepaid weeks, described as $195 per month, with shipments every 28 days and a payment-plan option.
Sources: [4] [11]
Service area: iThriveMD advertises telehealth across California and Arizona with the same member pricing; its directory lists several California addresses and Scottsdale as a telehealth appointment.
Sources: [8] [7]

Start with the recurring charge, not the introductory discount

The standard semaglutide page lists a $199 monthly option with $100 off, followed by $299 per month. The tirzepatide page follows the same structure: $299 initially, then $399 per month. Both describe billing every 28 days and no long-term commitment for the monthly option. The homepage limits the $100 promotion to the first month, excludes package purchases and says regular pricing resumes afterward. These are introductory offers, not continuing discounted rates.

A 28-day billing interval is not a calendar month. That distinction affects when a charge appears relative to a paycheck or other monthly expenses, even without calculating an annual total. iThriveMD’s general notice also says all memberships are charged every 28 days from their start date. Before enrolling, request the first charge date, the next charge date and the exact recurring amount in writing. Our explanation of four-week and prepaid billing provides a framework for reading those answers.

Tirzepatide’s product page says the price stays the same regardless of dose. That is a useful provider-specific assurance, although the supplied evidence also flags broader weight-loss language suggesting cost can depend on dose. The practical resolution is a quote naming the chosen program and identifying whether medication, clinical services, testing and delivery are included. The offer does not establish a particular vial size, concentration or quantity from the advertised billing period alone.

Sources: [5] [6] [8] [3]

Package prices require a written total

The standard medication packages display attractive dollar figures, but their labels should not be mistaken for complete checkout totals. Semaglutide lists $269.10 for its “3-month” option, $254.15 for “6-month” and $239.20 for “12-month.” The corresponding terms specify 12, 24 and 48 weeks paid upfront, with shipments every 28 days. Each also advertises a payment plan. The supplied pages do not unambiguously reconcile the displayed rate with the total amount collected.

Tirzepatide’s standard packages use the same structure, displaying $299.25, $259.35 and $199.50 for the three package lengths. The provider advertises discounts of 25%, 35% and 50%, respectively. Semaglutide’s corresponding discounts are 10%, 15% and 20%. These are the clinic’s advertised comparisons, not independently established savings. The table preserves the displayed prices and time descriptions without converting them into an inferred upfront bill or a calendar-year cost.

The package names are shorthand: 12 weeks is not three full calendar months, and 48 weeks is not a full calendar year. Nor does a package duration establish the medication quantity supplied or settle every obligation associated with leaving early. Ask for an itemized purchase agreement showing the total, shipment schedule and renewal interval. That agreement should also explain whether a payment plan replaces upfront collection or involves a separate financing arrangement.

Published standard-package figures for compounded injectable medication; displayed amounts are not verified total purchase prices.
Package label and prepaid period	Semaglutide displayed figure	Tirzepatide displayed figure
3-month: 12 weeks	$269.10; advertised 10% off	$299.25; advertised 25% off
6-month: 24 weeks	$254.15; advertised 15% off	$259.35; advertised 35% off
12-month: 48 weeks	$239.20; advertised 20% off	$199.50; advertised 50% off
Terms accompanying each package	Ships every 28 days; payment plan available	Ships every 28 days; payment plan available

Sources: [5] [6]

Automatic renewal changes the meaning of a prepaid purchase

The homepage states that all packages are paid in full at purchase and automatically renew at the interval associated with the selected package. That is materially different from buying a one-time course that simply ends. Yet the product pages advertise payment plans, while the general membership notice describes charges every 28 days. These statements may apply differently to different arrangements, but the supplied documentation does not explain precisely how they fit together.

The payment-plan offer should therefore be treated as an option needing terms, not as proof that everyone must prepay or that installment financing is interest-free. The evidence does not identify a financing company, interest rate, approval requirements or installment schedule. Ask whether there are separate clinic and financing obligations, which amount renews automatically and whether a promotional or discounted package rate applies again. No published appointment window establishes a continuing price guarantee.

The supplied terms do not establish a cancellation procedure, notice deadline, cancellation fee or refund policy. The monthly offer’s “no long-term commitment” language does not supply those missing details, and stopping renewal does not necessarily produce a refund for an existing purchase. Before paying, obtain the cancellation contact route and written treatment of unused services or medication. Our guide to cancellation and refunds explains why those are separate questions.

Sources: [8] [3] [5] [6]

Microdosing is a separate tirzepatide offer

iThriveMD says its microdosing protocols use tirzepatide only; it separately offers semaglutide maintenance plans for people who have completed a full GLP weight-loss program. Microdosing has clearer published package totals than the standard medication tables. The three-month listing is $585 for 12 prepaid weeks, described as $195 per month. It specifies shipments every 28 days and offers a payment plan. This is not the same offer as standard tirzepatide’s introductory monthly option.

The six-month microdosing package lists $1,053 for 24 prepaid weeks, an advertised 10% discount and a $175.50 monthly equivalent. The twelve-month option lists $1,755 for 48 prepaid weeks, an advertised 25% discount and a $146.25 monthly equivalent. Both specify shipments every 28 days and payment-plan availability. The six-month page also advertises $20 monthly savings, a figure that does not exactly match the difference between its displayed monthly equivalents.

This program includes an initial 30-minute consultation and monthly 15-minute follow-ups. Its enrollment language says no particular BMI or lab work is required, contrasting with the homepage’s statement that baseline labs precede any plan. That difference matters to both expectations and potential testing costs. The provider describes microdosing as off-label and states, “The FDA has not specifically studied or approved these lower doses.” Its marketing should not be read as proof of equivalent outcomes.

Sources: [11] [4] [8]

What the payment appears to buy—and what remains unpriced

The general weight-loss page says each plan includes monthly consultations, metabolic lab testing and real-time progress tracking. The semaglutide page adds clinical oversight and coaching. Those are meaningful service descriptions, but they do not fully itemize every program’s bill. In particular, the supplied evidence does not establish whether every advertised diagnostic test is included without an additional charge, or how the general testing promise applies to the microdosing program’s enrollment-without-labs language.

The published intake process starts with an online questionnaire about health and goals, followed by a clinical consultation reviewing diagnostic labs and a personalized plan. Eligible patients can begin treatment in clinic or at home, with ongoing progress tracking and plan adjustments. For tirzepatide, iThriveMD advertises injection training at the first visit, video tutorials and continuing support. It does not publish clear clinical-review turnaround times, appointment availability or support response times in the supplied excerpts.

The broader business also advertises B12 injections, IV therapy, hormone replacement therapy and advanced diagnostic testing. Those offerings should not automatically be counted as benefits of a GLP-1 purchase. Ask which services belong to the specific quoted package and which are separately purchased. A useful comparison follows our guide to what program prices include: compare the documented care bundle, not simply the medication headline or the clinic’s entire menu.

Sources: [10] [5] [8] [6] [4]

Insurance, eligibility and the people behind the service

For tirzepatide, iThriveMD explicitly says it does not accept insurance and states that HSA or FSA funds can be used for payment. For semaglutide, the wording is more conditional: patients may be able to use those funds, and the clinic can provide documentation for potential reimbursement when a plan includes out-of-network benefits. Neither statement guarantees reimbursement or account eligibility. The broader weight-loss page says insurance and a referral are not required.

The clinic offers free eligibility assessments and says diabetes is not required for its GLP program. Its general guidance describes possible qualification for adults with BMI over 27 plus weight-related conditions, or BMI over 30. These are provider descriptions, not an individualized approval decision. The supplied evidence does not provide a complete exclusion list or a numeric minimum age. Microdosing’s separate enrollment language should not be substituted for the standard program’s stated criteria.

iThriveMD identifies Samir Damani, MD, as founder and cardiovascular specialist, and Aubrey Anderson and Thomas Macsay as naturopathic doctors; Macsay is also listed as VP of Clinical Operations. These are the provider’s descriptions, not independently verified credentials. A referral disclosure names Vishal Verma, Samir Damani, Empower Aesthetics Medical Group, Inc. and iThriveMD PC, with financial or service relationships among listed parties. Ask which clinician and entity will provide and bill for your care.

Sources: [9] [8] [10] [11] [6] [5]

Geography, dispensing and delivery affect the real cost

The homepage advertises telehealth throughout California and Arizona at the same member pricing. The directory lists California addresses in Roseville, Walnut Creek, Sunnyvale and Laguna Niguel, while Scottsdale appears as a telehealth appointment rather than a confirmed physical clinic. The broader location claims do not reconcile into one verified count of in-person sites. Confirm the appointment format and exact location before allowing travel costs or an assumed nearby injection visit to shape the comparison.

The tirzepatide page offers home shipment or clinic visits for support and injections. The semaglutide page says medication is dispensed by a LegitScript-certified facility, but the supplied excerpt does not identify that facility by name. This is an attributed certification statement, not independent pharmacy verification, and dispensing does not establish who compounds the medication. Request the preparing and dispensing pharmacy’s name, location and contact information before purchase, along with the prescription-specific formulation and presentation.

The package pages describe shipment every 28 days, not arrival every 28 days. The evidence does not establish the carrier, shipping charge, transit time, refrigeration arrangements or replacement policy for damaged or delayed deliveries. Those omissions leave both service and budget questions unresolved. FDA advises not using an injectable GLP-1 drug that arrives warm or with insufficient refrigeration, and contacting the provider or dispensing pharmacy. A replacement policy should be clarified before a delivery problem occurs.

Sources: [8] [7] [6] [5] [1]

Price transparency is not clinical validation

iThriveMD describes its semaglutide and tirzepatide offerings as compounded preparations customized to dosing needs, administered through subcutaneous injections. Its own disclosure acknowledges that compounded drugs have not been reviewed or approved by FDA for safety or effectiveness and that results have not been independently verified. FDA approval concerns specific products, not a clinic. Nonapproval alone does not establish clinical inequivalence, but a published price or a customization claim also does not establish clinical performance.

FDA recommends compounded drugs when an individual’s medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy. That recommendation is important context for discussing why a compounded preparation is being offered; it is not a blanket legal conclusion about this provider. FDA also reports medication-measurement and administration errors involving compounded products. Readers should clarify instructions with their prescriber or pharmacist rather than derive a dose from pricing pages or this review.

The microdosing page acknowledges possible digestive or appetite-related effects despite more reassuring promotional language elsewhere. It should not be interpreted as a side-effect-free alternative. NIDDK advises that medication selection consider health conditions, other medicines, benefits, side effects and cost, with follow-up addressing tolerance and response. For budgeting, that means evaluating actual clinical access alongside renewal charges. A lower advertised package rate cannot substitute for a clear plan when treatment needs change or problems arise.

Sources: [11] [3] [4] [1] [2]

Questions & answers

Is iThriveMD’s $199 semaglutide price ongoing?

No. The standard monthly listing advertises $199 initially and $299 per month afterward, with billing every 28 days. The homepage says the $100 discount applies only to the first month and cannot be applied to package purchases. Confirm the next charge date and amount before enrolling, because the provider uses monthly language alongside a four-week billing interval.

Sources: [5] [8]

Does the lowest standard tirzepatide package figure mean that is all I pay?

The $199.50 figure appears on the standard “12-month” tirzepatide package, which specifies 48 weeks paid upfront, shipments every 28 days and payment-plan availability. It should not be treated as the complete purchase total. The supplied evidence does not unambiguously state that total or explain financing terms. Request a written checkout amount and renewal amount rather than calculating a bill from the headline.

Sources: [6] [8]

Are labs included, and are they required for microdosing?

The general weight-loss page says plans include metabolic lab testing, and the homepage says baseline labs occur before any plan begins. The microdosing page instead says lab work is not required to enroll. Those statements need program-specific clarification. Ask which tests are required before prescribing, which are included in your quoted price and whether later monitoring can create a separate charge.

Sources: [10] [8] [4]

Can I use insurance or an HSA/FSA at iThriveMD?

The tirzepatide page says insurance is not accepted for that treatment and that HSA/FSA funds can be used. Semaglutide’s page says those funds may be usable and offers documentation for potential out-of-network reimbursement. These are not guarantees from your insurer or account administrator. Confirm the particular expense independently and ask the clinic what documentation it supplies before relying on reimbursement in your budget.

Sources: [6] [5]

Can Arizona patients visit the Scottsdale location?

The supplied directory labels Scottsdale as a telehealth appointment, not a confirmed in-person clinic. iThriveMD advertises telehealth in Arizona and California at the same member pricing, and lists physical addresses for several California locations. Ask the clinic to confirm where your consultation and any injection support would occur. Do not assume a city listing guarantees a local walk-in or treatment site.

Sources: [7] [8]

How do I stop renewal or obtain a refund?

The supplied documentation does not establish the cancellation contact route, required notice, fees or refund rules. It does say packages renew automatically, while monthly options advertise no long-term commitment. Before purchasing, ask for written instructions covering both ending future renewal and handling money already paid. Those are separate issues; cancellation language alone does not establish a refund entitlement or a repayment timeline.

Sources: [8] [5] [6] [3]

Our assessment

iThriveMD documents more than a headline price: it publishes introductory and subsequent charges, several package options, consultation components and choices between home treatment and clinic support. That makes comparison possible. The remaining weaknesses are consequential, however: standard-package totals, payment-plan terms, overlapping billing language, pharmacy identity and cancellation/refund boundaries are not fully resolved in the supplied evidence. A sensible next step is a written, program-specific quote identifying the first payment, future charges, included testing, dispensing pharmacy and exit procedure. Until those details are supplied, the lowest displayed figure is an incomplete basis for judging affordability—not proof of poor care, but not a complete financial commitment either.

Visit iThriveMD’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

iThriveMD Review: The First GLP-1 Price Is Only Part of the Cost

At a glance

01Start with the recurring charge, not the introductory discount

02Package prices require a written total

03Automatic renewal changes the meaning of a prepaid purchase

04Microdosing is a separate tirzepatide offer

05What the payment appears to buy—and what remains unpriced

06Insurance, eligibility and the people behind the service

07Geography, dispensing and delivery affect the real cost

08Price transparency is not clinical validation